Pioneering a Novel Therapeutic Approach via Direct Vagus Nerve Injection

Giant Axonal Neuropathy (GAN) is a devastating rare neurodegenerative disease that affects the autonomic nervous system (ANS). Previous clinical trials using intrathecal administration (IT) showed some benefit in alleviating central and peripheral nervous system symptoms, but had limited efficacy in addressing autonomic nervous system dysfunction, which causes respiratory distress and difficulty swallowing. To address this, researchers at the University of Texas Southwestern Medical Center (UT Southwestern) have developed an innovative approach: direct injection of the gene therapy scAAV9/JeT-GAN into the left vagus nerve. This intraneural injection directly targets autonomic neurons and has the potential to be a significant turning point in preventing life-threatening respiratory complications, which have been a major challenge in previous treatments.

Continuation of Academic-Led Clinical Trial Following Taysha's Commercial Withdrawal

This clinical trial (NCT07543991) is a Phase 1, open-label study that will administer a single dose to four patients who previously received intrathecal gene therapy. Originally, this program was being developed by Taysha Gene Therapies (TSHA), a Nasdaq-listed company, under the pipeline name 'TSHA-120,' with plans for commercialization. However, in September 2023, after a meeting with the U.S. Food and Drug Administration (FDA), the development was halted due to the requirement for a controlled clinical trial design. Despite this, Hannah's Hope Fund, a patient advocacy group, and UT Southwestern, the original academic developer, have continued the research, making it a model case for the development of treatments for rare diseases beyond commercial barriers. The researchers plan to conduct a three-year long-term follow-up study to focus on verifying the safety and efficacy of vagus nerve delivery in restoring autonomic nervous system function.

The Value of the First Gene Therapy Platform Targeting the Autonomic Nervous System

From a technical perspective, this trial is noteworthy as the first in the world to directly administer a gene vector to the vagus nerve, the most important autonomic nerve in the human body, attracting attention from the bio-industry. The scAAV9/JeT-GAN vector used in the trial is designed to deliver an optimized gene sequence to address the underlying cause of GAN, which is a deficiency in the gigaxonin protein. If this intraneural injection platform proves to be safe, it could be expanded to other difficult-to-treat neurodegenerative diseases, such as Parkinson's disease or multiple system atrophy (MSA), which involve autonomic nervous system dysfunction. This could lead to the development of a valuable technology platform for gene delivery targeting the autonomic nervous system, going beyond a single rare disease treatment.

Unmet Medical Needs and Prospects for the Ultra-Rare Disease Treatment Market

Currently, there are no disease-modifying therapies approved by regulatory agencies for the treatment of GAN, and supportive care, such as respiratory management, is the only available option. Although GAN is an ultra-rare disease with fewer than a few hundred patients worldwide, the market is projected to grow from approximately USD 126 million in 2025 to USD 186 million in 2032, with an annual growth rate of 5.7%. Due to the nature of gene therapies, high pricing is possible upon approval, and the potential for market exclusivity allows for strong margins and cash flow upon successful commercialization. Venture capital (VC) and institutional investors are looking for opportunities to recoup their investments through technology transfer (out-licensing) or new biotech spin-outs, based on the safety data from this trial.